PMC:7537941 / 18822-19127 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T138","span":{"begin":286,"end":294},"obj":"Disease"},{"id":"T139","span":{"begin":295,"end":304},"obj":"Disease"}],"attributes":[{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"However, the significant differences in patient characteristics between the PROWESS trials has led to the recommendation that a trial of DrotAA should be repeated using an optimised study design [68], and this could include a trial in a less heterogeneous high-risk population, such as COVID-19 pneumonia."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T184","span":{"begin":91,"end":94},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T185","span":{"begin":126,"end":127},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T186","span":{"begin":224,"end":225},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T187","span":{"begin":235,"end":236},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"However, the significant differences in patient characteristics between the PROWESS trials has led to the recommendation that a trial of DrotAA should be repeated using an optimised study design [68], and this could include a trial in a less heterogeneous high-risk population, such as COVID-19 pneumonia."}

{"project":"LitCovid-PubTator","denotations":[{"id":"564","span":{"begin":40,"end":47},"obj":"Species"},{"id":"580","span":{"begin":286,"end":304},"obj":"Disease"}],"attributes":[{"id":"A564","pred":"tao:has_database_id","subj":"564","obj":"Tax:9606"},{"id":"A580","pred":"tao:has_database_id","subj":"580","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"However, the significant differences in patient characteristics between the PROWESS trials has led to the recommendation that a trial of DrotAA should be repeated using an optimised study design [68], and this could include a trial in a less heterogeneous high-risk population, such as COVID-19 pneumonia."}

{"project":"MyTest","denotations":[{"id":"33004529-23826709-29393028","span":{"begin":196,"end":198},"obj":"23826709"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"However, the significant differences in patient characteristics between the PROWESS trials has led to the recommendation that a trial of DrotAA should be repeated using an optimised study design [68], and this could include a trial in a less heterogeneous high-risk population, such as COVID-19 pneumonia."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T77","span":{"begin":295,"end":304},"obj":"Phenotype"}],"attributes":[{"id":"A77","pred":"hp_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"However, the significant differences in patient characteristics between the PROWESS trials has led to the recommendation that a trial of DrotAA should be repeated using an optimised study design [68], and this could include a trial in a less heterogeneous high-risk population, such as COVID-19 pneumonia."}

{"project":"2_test","denotations":[{"id":"33004529-23826709-29393028","span":{"begin":196,"end":198},"obj":"23826709"}],"text":"However, the significant differences in patient characteristics between the PROWESS trials has led to the recommendation that a trial of DrotAA should be repeated using an optimised study design [68], and this could include a trial in a less heterogeneous high-risk population, such as COVID-19 pneumonia."}

{"project":"LitCovid-sentences","denotations":[{"id":"T106","span":{"begin":0,"end":305},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"However, the significant differences in patient characteristics between the PROWESS trials has led to the recommendation that a trial of DrotAA should be repeated using an optimised study design [68], and this could include a trial in a less heterogeneous high-risk population, such as COVID-19 pneumonia."}